Evidence map›Paper›PMID 38060141›Full record

ArticleWorld journal of pediatrics : WJP2024

Mesenchymal stem cell-based TRAIL delivery inhibits the metastatic state of clinical therapy-resistant progressive neuroblastoma.

Dinesh Babu Somasundaram, Andrew Maher, Sheeja Aravindan, Zhongxin Yu, Brian M Besch, Natarajan Aravindan

Abstract readLetter
PubMed Publisher
In one paragraph

Article in World journal of pediatrics : WJP, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Dinesh Babu SomasundaramDepartment of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Andrew MaherDepartment of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Sheeja AravindanStephenson Cancer Center, Oklahoma City, OK, USA.
Zhongxin YuDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Brian M BeschDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Natarajan AravindanDepartment of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. naravind@ouhsc.edu.ORCID 0000-0001-9150-3911
University of Oklahoma Health Sciences Center · USOklahoma State University Oklahoma City · US

Funding

TUMOR RESISTANCE MECHANISMS TO ANTI-VEGF THERAPY IN PROSTATE CANCER (Sukyung Woo)P20GM103639 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI DHANASEKARAN, DANNY N. · 2012 to 2022
$21.3M
NIH HHS P20GM103639
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Mesenchymal Stem CellsNeuroblastomaApoptosisHumans

Identifiers

PMID38060141
OpenAlexW4389437746

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.